143.26
price up icon0.94%   1.34
after-market アフターアワーズ: 143.26
loading
前日終値:
$141.92
開ける:
$142.85
24時間の取引高:
907.14K
Relative Volume:
0.96
時価総額:
$14.50B
収益:
$2.24B
当期純損益:
$385.90M
株価収益率:
38.41
EPS:
3.73
ネットキャッシュフロー:
$440.10M
1週間 パフォーマンス:
+1.67%
1か月 パフォーマンス:
+4.81%
6か月 パフォーマンス:
-0.96%
1年 パフォーマンス:
+4.48%
1日の値動き範囲:
Value
$141.57
$144.82
1週間の範囲:
Value
$138.46
$144.82
52週間の値動き範囲:
Value
$110.95
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1174)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,700
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
143.26 14.50B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.89 74.84B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.24 41.78B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
12.92 40.96B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
21.92 24.83B 16.77B -959.00M 1.37B -0.85

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Jan 19, 2025

Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Neurocrine Bio stock retains outperform rating on robust pipeline - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Avanza Fonder AB Invests $1.80 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Kyle Gano Sells 65,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock By Investing.com - Investing.com UK

Jan 17, 2025
pulisher
Jan 16, 2025

How To Trade (NBIX) - Stock Traders Daily

Jan 16, 2025
pulisher
Jan 16, 2025

Endometriosis Pipeline 2024: Detailed Clinical Trials - openPR

Jan 16, 2025
pulisher
Jan 16, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co. - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law

Jan 15, 2025
pulisher
Jan 15, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $164.81 Consensus PT from Brokerages - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

40 Under 40: Ashley Allan, Neurocrine Biosciences - MM+M Online

Jan 14, 2025
pulisher
Jan 13, 2025

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewswire

Jan 13, 2025
pulisher
Jan 09, 2025

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.

Jan 09, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - Investing.com

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences explores new CAH treatments By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Bio stock overweight rating held on positive outlook By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $162.00 - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences explores new CAH treatments - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences (NBIX) Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism - Longview News-Journal

Jan 08, 2025
pulisher
Jan 08, 2025

Neurocrine Biosciences (NASDAQ:NBIX) shareholders have earned a 22% CAGR over the last three years - Simply Wall St

Jan 08, 2025
pulisher
Jan 07, 2025

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald

Jan 07, 2025
pulisher
Jan 06, 2025

NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

How to Take Advantage of moves in (NBIX) - Stock Traders Daily

Jan 06, 2025
pulisher
Jan 06, 2025

Neurocrine Biosciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025
pulisher
Jan 03, 2025

Neurocrine Biosciences executive sells $37,563 in stock By Investing.com - Investing.com Nigeria

Jan 03, 2025
pulisher
Jan 03, 2025

Ingrid Delaet Sells 272 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

Neurocrine Biosciences executive sells $37,563 in stock - Investing.com India

Jan 03, 2025
pulisher
Jan 02, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat

Jan 02, 2025
pulisher
Dec 27, 2024

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia - Marketscreener.com

Dec 27, 2024
pulisher
Dec 25, 2024

Neurocrine Biosciences to Participate at Investor Conferences in December - cnhinews.com

Dec 25, 2024
pulisher
Dec 25, 2024

Principal Financial Group Inc. Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 25, 2024
pulisher
Dec 24, 2024

Neurocrine Biosciences Stock Sees RS Rating Upgrade - Yahoo! Voices

Dec 24, 2024
pulisher
Dec 24, 2024

NBIX: 3 Specialty Pharma Stocks Addressing Unmet Medical Needs - StockNews.com

Dec 24, 2024
pulisher
Dec 24, 2024

Q1 EPS Forecast for Neurocrine Biosciences Lifted by Analyst - MarketBeat

Dec 24, 2024
pulisher
Dec 23, 2024

Neurocrine Biosciences, Inc. Selects PANTHERx®Rare Specialty Pharmacy for Distribution of Crenessity™ (crinecerfont) - StreetInsider.com

Dec 23, 2024
pulisher
Dec 23, 2024

Neurocrine Bio shares expected to grow with robust U.S. sales forecast for Crenessity - Investing.com UK

Dec 23, 2024
pulisher
Dec 23, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Receives "Overweight" Rating from Piper Sandler - MarketBeat

Dec 23, 2024
pulisher
Dec 23, 2024

Barclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $165.00 - MarketBeat

Dec 23, 2024
pulisher
Dec 23, 2024

Sanctuary Advisors LLC Buys 3,898 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 23, 2024
pulisher
Dec 21, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

BofA raises Neurocrine Bio target to $182 on drug launch By Investing.com - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter

Dec 20, 2024
pulisher
Dec 20, 2024

Needham & Company LLC Reiterates Hold Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences (NBIX) Announces Commercial Availability of CRENESSITY for Children and Adults With Classic Congenital Adrenal Hyperplasia - StreetInsider.com

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire

Dec 20, 2024

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Neurocrine Biosciences Inc (NBIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Gano Kyle
Chief Executive Officer
Jan 15 '25
Sale
141.50
65,000
9,197,550
135,392
$11.30
price down icon 0.35%
$126.20
price down icon 0.05%
$91.47
price down icon 0.12%
$12.02
price up icon 0.08%
$29.47
price down icon 0.94%
大文字化:     |  ボリューム (24 時間):